Following the positive vote of the ethics committee at Lübeck University, DZL implements a broad consent for children. ARCN’s biobank BioMaterialBank Nord was in charge of this project.
Prof. Dr. Klaus Rabe and Prof. Dr. Tobias Welte received the ‚Ehrenpreis‘ of the Society for Pediatric Pneumology (GPP) for the year 2020 which was awarded for the first time.
Professor Didier Stainier receives 2.5 million euros from the European Research Council.
Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be...
To date, pirfenidone has only been used for the treatment of Idiopathic Pulmonary Fibrosis (IPF). DZL researchers have now investigated whether this drug may also help in the treatment of other progressive fibrotic interstitial lung...
Analysing copy number variations (CNVs) of tumour DNA extracted from blood samples of patients with ALK-positive non-small-cell lung cancer can provide valuable information on therapy response and has the potential to improve therapy control.
The objective of future personalized medicine is the early detection of a disease in its preclinical stage when the patient is still healthy. In order to achieve this, a more thorough understanding as to the...
Ein einfaches Blutbild mit Bestimmung des Monozyten-Werts kann Prognosevorhersagen über den Krankheitsverlauf von Patienten mit idiopathischer Lungenfibrose (IPF) erlauben.
Patients with severe idiopathic pulmonary fibrosis (IPF) often develop additional pulmonary hypertension. A clinical trial investigated whether treatment with Sildenafil (approved for PH) when administered in addition to the pulmonary fibrosis medication pirfenidone is effective.
Primary Ciliary Dyskinesia (PCD) is a rare little investigated hereditary systemic disease. DZL scientists have now succeeded in producing induced pluripotent stem cells, with which unlimited amounts of test material can be manufactured.
A team of DZL researchers has developed a novel tool to measure the activity of two proteins implicated in lung inflammation in cystic fibrosis.
DZL-Researchers have now succeeded in curing COPD in mice. Their goal is to test the novel therapeutic approach in human clinical trials over the next few years.
